問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2213Cases

2014-04-01 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-11-01 - 2014-11-30

Phase III

A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects with Essential Hypertension who are Inadequately Controlled on Nifedipine Gastrointestinal Therapeutic System Monotherapy

  • Condition/Disease

    Treatment of essential hypertension inadequately controlled by monotherapy

  • Test Drug

    BAY 98-7106( Nifedipine GITS / Candesartan cilexetil fixed dose combination)

Participate Sites
5Sites

Terminated5Sites

2013-05-01 - 2017-09-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-02-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-12-27 - 2021-03-22

Phase I

A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    DS-1205c

Participate Sites
9Sites

Terminated7Sites

夏和雄
Taipei Medical University Hospital

李岡遠
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

未分科

2020-02-25 - 2021-05-05

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-05-01 - 2023-08-25

Phase II/III

A Phase 2/3 Study of AMG531 in Patients With Aplastic Anemia Previously Untreated With Immunosuppressive Therapy

  • Condition/Disease

    Aplastic Anemia

  • Test Drug

    AMG531

Participate Sites
5Sites

Terminated5Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2020-10-01 - 2021-10-01

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-07-01 - 2020-06-30

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Terminated2Sites

1 144 145 146 147 148 222
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB